# EDGAR Filing Document

**Accession Number:** 0001840292
**File Stem:** 0001840292-23-000011
**Filing Date:** 2023-3
**Character Count:** 21375
**Document Hash:** 35d9bb0d32f845a98a0e1e24033861c4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001840292-23-000011.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001840292-23-000011

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230328

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Heliogen, Inc.
- **CENTRAL INDEX KEY:** 0001840292
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTRIC SERVICES [4911]
- **IRS NUMBER:** 854204953
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40209
- **FILM NUMBER:** 23769752

**BUSINESS ADDRESS:**
- **STREET 1:** 130 W UNION ST.
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91103
- **BUSINESS PHONE:** 9709240446

**MAIL ADDRESS:**
- **STREET 1:** 130 W UNION ST.
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Athena Technology Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210112

?xml version="1.0" ? hlg-20230328

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 28, 2023

**Heliogen, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40209** | **85-4204953** |
| (State or other jurisdiction of<br>incorporation) | (Commission File Number) | (I.R.S. Employer <br>Identification No.) |

---

**130 West Union Street**

**Pasadena, California 91103**

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(626) 720-4530**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.0001 par value per share | HLGN | New York Stock Exchange |
| Warrants, each whole warrant exercisable for shares of Common stock at an exercise price of $11.50 per share | HLGN.W | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⌧

------

**Item 2.02 Results of Operations and Financial Condition.**

On March 28, 2023, Heliogen, Inc. issued a press release announcing information regarding its results of operations and financial condition for the fourth quarter and full year 2022, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | <u>[Press Release of Heliogen, Inc. dated March 28, 2023](ex991heliogenq42022-earnin.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **Heliogen, Inc.** |
| Dated: | March 28, 2023 | By: | /s/ Kelly Rosser |
|  |  |  | **Kelly Rosser** |
|  |  |  | **Interim Chief Financial Officer** |

---

## Exhibit 99.1

**Exhibit 99.1**

**Heliogen, Inc. Announces Fourth Quarter and Full Year 2022**

**Financial and Operational Results; Reports Progress on Strategic Initiatives** 

**PASADENA, CA, March 28, 2023** – Heliogen, Inc. ("Heliogen") (NYSE: HLGN), a leading provider of AI-enabled concentrating solar energy technology, today provided its fourth quarter and full year 2022 financial and operational results.

**Recent Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Completed the preliminary design and secured a site for the "Proxima" green hydrogen project in Lancaster, CA

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Achieved successful accumulation of over 125 hours of operational life and 25 miles travelled on the ChariotAV, Heliogen's autonomous cleaning vehicle

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Following the leadership transition of Heliogen's CEO in February 2023, announced Strategic Plan and formed Board-level Corporate Strategy Committee to oversee the implementation of Heliogen's long-range strategic plan and specific strategic initiatives

**Full-Year 2022 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Signed full project agreement with Woodside Energy (USA) Inc. ("Woodside") for the commercial-scale demonstration and deployment of Heliogen's AI-enabled concentrated solar energy technology; this project will also demonstrate other novel elements through application of Heliogen's $39 million U.S. Department of Energy ("DOE") award

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Finalized and executed a lease in the Brenda Solar Energy Zone with U.S. Bureau of Land Management for a green hydrogen production project that is under development

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Successfully performed automated installation of prototype Generation 5 heliostats at Lancaster demonstration facility

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Successfully completed initial field testing of ChariotAV

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Selected to receive an additional $4.1 million award from the DOE to accelerate the large-scale development and deployment of a solar thermal calciner to decarbonize cement production

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Completed the build-out of Heliogen's automated, high-volume heliostat production facility in Long Beach, CA

**Executive Commentary** 

"Our journey in 2022 was marked by many significant strides forward but also some humbling setbacks. While we made progress on our technical and execution goals, we fell short of our commercial contract goals," said Christie Obiaya, who in February 2023 was appointed by Heliogen's Board of Directors to succeed Bill Gross as Heliogen's Chief Executive Officer.

Ms. Obiaya continued, "Upon stepping into the CEO role last month, I have been taking swift action with a renewed focus on growing sales through improving our product-market fit; on deployment of our commercial scale projects; and on extending our cash runway. We've already made meaningful progress on these initiatives, and we will continue to execute on this roadmap."

------

**Fourth Quarter 2022 Financial Results** 

For the fourth quarter 2022, Heliogen reported total revenue of $4.7 million and net loss of $35.0 million. Heliogen's net loss was driven primarily by the growth of Heliogen's operations to support its commercial-scale demonstration agreement with Woodside, including personnel costs such as a non-cash share-based compensation expense of $8.2 million and a non-cash asset impairment charge of $6.9 million. Heliogen's Adjusted EBITDA, which excludes the non-cash share-based compensation expense and other impacts, was negative $25.8 million for the fourth quarter 2022.

**Full Year 2022 Financial Results**

For the full year 2022, Heliogen reported total revenue of $13.8 million and net loss of $142.0 million. Heliogen's net loss was driven primarily by a non-cash share-based compensation expense of $42.6 million, the recognition of a provision for contract losses of $33.8 million and a non-cash asset impairment charge of $6.9 million, partially offset by non-cash, remeasurement impacts of $13.9 million related to our warrants. Heliogen's Adjusted EBITDA, which excludes these and other impacts, was negative $81.0 million for full year 2022.

As Heliogen focuses on growing its revenue backlog, progressing its commercial projects and reducing its cost structure, the Company has decided not to issue financial guidance at this time.

**Conference Call Information**

The Heliogen management team will host a conference call to discuss its fourth quarter and full year 2022 financial results on Wednesday, March 29, 2023, at 10:00 a.m. EDT. The call can be accessed via a live webcast accessible on the Events & Presentations page in the Investor Relations section of Heliogen's website at www.heliogen.com. The call can also be accessed live via telephone by dialing 1-877-407-0789 (1-201-689-8562 for international callers) and referencing Heliogen.

An archive of the webcast will also be available shortly after the call on the Investor Relations section of Heliogen's website.

**Open Conference Call Question Submission**

Members of the investor community may submit questions before the start of the conference call for consideration via email to louis.baltimore@heliogen.com.

**About Heliogen**

**Use of Non-GAAP Financial Information**

Management uses certain financial measures, including EBITDA and Adjusted EBITDA, to evaluate our financial and operating performance that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America ("GAAP"). We believe these non-GAAP financial measures are useful to investors and analysts to assess our ongoing financial performance because they provide improved comparability between periods through the exclusion of certain items that we believe are not indicative of our core operating performance, enhance the overall understanding of our past financial performance

------

and future prospects, and remove items that may obscure our underlying business results and trends. These measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP, and our calculations thereof may not be comparable to similarly titled measures reported by other companies.

EBITDA represents consolidated net loss before (i) interest (income) expense, net, (ii) income tax expense (benefit) and (iii) depreciation and amortization expense. We define Adjusted EBITDA as EBITDA adjusted for certain significant non-cash items and items that management believes are not attributable to or indicative of our on-going operations or that may obscure our underlying results and trends. Please see the accompanying tables for a reconciliation of net loss to EBITDA and Adjusted EBITDA.

**Forward-Looking Statements** 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical in nature, including the words "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the development of our production facilities, building our revenue backlog, progressing our commercial projects, reducing our cost structure, achieving our financial and operational goals and future growth opportunities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder; (ii) changes in our business and strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; (iii) our ability to execute our business model, including market acceptance of our planned products and services and achieving sufficient production volumes at acceptable quality levels and prices; (iv) our ability to maintain listing on the New York Stock Exchange; (v) our ability to access sources of capital to finance operations, growth and future capital requirements; (vi) our ability to maintain and enhance our products and brand, and to attract and retain customers; (vii) our ability to scale in a cost effective manner; (viii) changes in applicable laws or regulations; (ix) developments and projections relating to our competitors and industry; and (x) our ability to protect our intellectual property. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the "Risk Factors" section in Part I, Item 1A in our Annual Report on Form 10-K/A for the annual period ended December 31, 2021 and other documents filed by Heliogen from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Heliogen assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

**Heliogen Investors Contact:**

Louis Baltimore

VP, Investor Relations

Louis.Baltimore@heliogen.com

**Heliogen Media Contact:**

Cory Ziskind

ICR, Inc.

HeliogenPR@icrinc.com

------

**Heliogen, Inc.**

**Condensed Consolidated Statements of Operations and Comprehensive Loss**

*($ in thousands, except per share and share data)*

*(unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Revenue | $4720 | $5241 | $13751 | $8804 |
| Cost of revenue | 3475 | 6711 | 47536 | 9447 |
| **Gross profit (loss)** | 1245 | (1470) | (33785) | (643) |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 20491 | 14745 | 81224 | 29844 |
| &nbsp;&nbsp;&nbsp;Research and development | 11833 | 4587 | 38281 | 13478 |
| &nbsp;&nbsp;&nbsp;Impairment charges | 6922 |  | 6922 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 39246 | 19332 | 126427 | 43322 |
| **Operating loss** | (38001) | (20802) | (160212) | (43965) |
| &nbsp;&nbsp;&nbsp;Interest income, net | 329 | 227 | 995 | 634 |
| &nbsp;&nbsp;&nbsp;SAFE instruments remeasurement |  | (23914) |  | (86907) |
| &nbsp;&nbsp;&nbsp;Gain (loss) on warrant remeasurement | 1242 | (4047) | 13921 | (6651) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 1209 | (205) | 2280 | (517) |
| **Net loss before taxes** | (35221) | (48741) | (143016) | (137406) |
| &nbsp;&nbsp;&nbsp;Benefit (provision) for income taxes | 235 | (2) | 1016 | (2) |
| **Net loss** | (34986) | (48743) | (142000) | (137408) |
| **Other comprehensive loss, net of taxes:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Unrealized losses on available-for-sale securities | 232 | (10) | (292) | (17) |
| &nbsp;&nbsp;&nbsp;Cumulative translation adjustment | 200 | 70 | (297) | 13 |
| **Total comprehensive loss** | $(34554) | $(48683) | $(142589) | $(137412) |
| **Loss per share:** |  |  |  |  |
| Loss per share – Basic and Diluted | $(0.18) | $(3.07) | $(0.75) | $(11.48) |
| Weighted average number of shares outstanding – Basic and Diluted | 193832571 | 15886477 | 190190057 | 11970550 |

---

------

**Heliogen, Inc.**

**Condensed Consolidated Balance Sheets**

*($ in thousands)*

*(unaudited)*

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2022** | **2021** |
| **ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $45719 | $190081 |
| &nbsp;&nbsp;&nbsp;Investments, available-for-sale | 97504 | 32332 |
| &nbsp;&nbsp;&nbsp;Other current assets | 15598 | 4770 |
| Total current assets | 158821 | 227183 |
| Non-current assets | 32798 | 30265 |
| **Total assets** | $191619 | $257448 |
| **LIABILITIES, CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS' EQUITY** |  |  |
| &nbsp;&nbsp;&nbsp;Trade payables | $6921 | $4645 |
| &nbsp;&nbsp;&nbsp;Contract liabilities | 10348 | 513 |
| &nbsp;&nbsp;&nbsp;Contract loss provisions | 28418 | 397 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 5602 | 6974 |
| Total current liabilities | 51289 | 12529 |
| Long-term liabilities | 15006 | 30861 |
| **Total liabilities** | 66295 | 43390 |
| **Shareholders' equity** | 125324 | 214058 |
| **Total liabilities, convertible preferred stock and shareholders' equity** | $191619 | $257448 |

---

------

**Heliogen, Inc.**

**Reconciliation of Net Loss to EBITDA and Adjusted EBITDA**

*($ in thousands)*

*(unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** | **2022** | **2021** |
| Net loss | $(34986) | $(48743) | $(142000) | $(137408) |
| &nbsp;&nbsp;Interest income, net | (329) | (227) | (995) | (634) |
| &nbsp;&nbsp;Provision (benefit) for income taxes | (235) | 2 | (1016) | 2 |
| &nbsp;&nbsp;Depreciation and amortization | 298 | 290 | 2587 | 562 |
| **EBITDA** | $(35252) | $(48678) | $(141424) | $(137478) |
| &nbsp;&nbsp;Impairment charges <sup>(1)</sup> | 6922 |  | 6922 |  |
| &nbsp;&nbsp;SAFE instruments remeasurement <sup>(2)</sup> |  | 23914 |  | 86907 |
| &nbsp;&nbsp;Loss (gain) on warrant remeasurement <sup>(3)</sup> | (1242) | 4047 | (13921) | 6651 |
| &nbsp;&nbsp;Share-based compensation <sup>(4)</sup> | 8169 | 9331 | 42647 | 11380 |
| &nbsp;&nbsp;Provision for contract losses <sup>(5)</sup> | 39 | 508 | 33776 | 508 |
| &nbsp;&nbsp;Contract losses incurred <sup>(5)</sup> | (2216) | (111) | (5718) | (111) |
| &nbsp;&nbsp;Change in fair value of contingent consideration <sup>(6)</sup> | (593) |  | (1656) |  |
| &nbsp;&nbsp;Employee retention credit <sup>(7)</sup> | (1579) |  | (1579) |  |
| **Adjusted EBITDA** | $(25752) | $(10989) | $(80953) | $(32143) |

---

________________

(1)Represents impairment charges related to construction in progress for certain project-related costs and intangible assets.

(2)Represents the change in fair value on our SAFE instruments which were converted to common stock immediately prior to the closing of the business combination with Athena Technology Acquisition Corp ("Athena").

(3)Represents the change in fair value on our warrant liabilities for the outstanding warrants that we assumed in the business combination with Athena.

(4)Share-based compensation for the three months and year ended December 31, 2022 excludes $0.1 million and $0.2 million, respectively, of expense associated with the issuance of warrants in April 2022 in connection with vendor agreements.

(5)Represents contract losses with customers for which estimated costs to satisfy performance obligations exceeded considerations expected to be realized. Contract loss is reduced and recognized in cost of revenue as expenditures are incurred and related revenue is recognized.

(6)Represents the change in fair value of our contingent consideration related to an acquisition completed in 2021.

(7)Represents the employee tax credit related to the CARES Act recorded as grant revenue in the fourth quarter of 2022.

<br>